spesolimab-话题@MedSci - 梅斯（MedSci）

#spesolimab#

3篇内容 | 1070人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2239443, encodeId=28352239443fe, content=<a href='/topic/show?id=4b3d104922f2' target=_blank style='color:#2F92EE;'>#spesolimab#</a> <a href='/topic/show?id=8fec121e4978' target=_blank style='color:#2F92EE;'>#小儿广泛性脓疱性银屑病#</a>, objectTitle=J Inflamm Res：我国学者成功使用Spesolimab治疗小儿广泛性脓疱性银屑病（GPP）, objectType=article, longId=852874, objectId=2ced8528e4d0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240614/1718360341111_92910.png, objectUrl=/article/show_article.do?id=2ced8528e4d0, replyNumber=0, likeNumber=17, createdTime=2024-11-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=2ced8528e4d0, moduleTitle=J Inflamm Res：我国学者成功使用Spesolimab治疗小儿广泛性脓疱性银屑病（GPP）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2ced8528e4d0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2115850, encodeId=44122115850cd, content=<a href='/topic/show?id=5cd3105302f2' target=_blank style='color:#2F92EE;'>#司柏索利单抗#</a>治疗中重度<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>的疗效和安全性，<a href='/topic/show?id=4b3d104922f2' target=_blank style='color:#2F92EE;'>#spesolimab#</a>, objectTitle=J Eur Acad Dermatol Venereol：司柏索利单抗治疗中重度特应性皮炎的疗效和安全性, objectType=article, longId=760277, objectId=b6b9e6027775, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221121/1669018493263_4754896.jpeg, objectUrl=/article/show_article.do?id=b6b9e6027775, replyNumber=0, likeNumber=115, createdTime=2023-02-22, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b6b9e6027775, moduleTitle=J Eur Acad Dermatol Venereol：司柏索利单抗治疗中重度特应性皮炎的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b6b9e6027775)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2106352, encodeId=745b210635244, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a><a href='/topic/show?id=456a966ee9' target=_blank style='color:#2F92EE;'>#IL-36R#</a>单抗<a href='/topic/show?id=c564105082ba' target=_blank style='color:#2F92EE;'>#佩索利单抗#</a><a href='/topic/show?id=4b3d104922f2' target=_blank style='color:#2F92EE;'>#spesolimab#</a>治疗<a href='/topic/show?id=ec6f6488874' target=_blank style='color:#2F92EE;'>#泛发性脓疱型银屑病#</a>, objectTitle=勃林格殷格翰IL-36R单抗spesolimab治疗银屑病在中国获批, objectType=article, longId=752204, objectId=ab9be52204ef, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221123/b0bdc609c9394292ac843dcac3e87f70.jpg, objectUrl=/article/show_article.do?id=ab9be52204ef, replyNumber=0, likeNumber=119, createdTime=2022-12-16, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ab9be52204ef, moduleTitle=勃林格殷格翰IL-36R单抗spesolimab治疗银屑病在中国获批, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ab9be52204ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2092807, encodeId=4379209280e77, content=<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a>批准的创新药物，如<a href='/topic/show?id=74ec10492098' target=_blank style='color:#2F92EE;'>#呋替巴替尼#</a>，<a href='/topic/show?id=a6f41049212a' target=_blank style='color:#2F92EE;'>#deucravacitinib#</a>，<a href='/topic/show?id=4b3d104922f2' target=_blank style='color:#2F92EE;'>#spesolimab#</a>，<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>，<a href='/topic/show?id=468410492308' target=_blank style='color:#2F92EE;'>#eflapegrastim#</a>等，<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>，皮肤风湿免疫仍然是大头。下部分应是<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a>一类, objectTitle=FDA在2022年第三季度批准了哪些创新药（上）？, objectType=article, longId=742664, objectId=ced9e4266497, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221009/ab2e59afdf774f8881a31e168706d9f7.jpg, objectUrl=/article/show_article.do?id=ced9e4266497, replyNumber=0, likeNumber=139, createdTime=2022-10-10, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced9e4266497, moduleTitle=FDA在2022年第三季度批准了哪些创新药（上）？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ced9e4266497)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 侠胆医心

FDA批准的创新药物，如呋替巴替尼，deucravacitinib，spesolimab，Selpercatinib，eflapegrastim等，肿瘤，皮肤风湿免疫仍然是大头。下部分应是罕见病一类

2022-10-10

梅斯管理员 (审核中...)

前往app查看评论内容

#spesolimab# #小儿广泛性脓疱性银屑病#

J Inflamm Res：我国学者成功使用Spesolimab治疗小儿广泛性脓疱性银屑病（GPP）

2024-11-27发表于陕西省

showtest (审核中...)

前往app查看评论内容

#司柏索利单抗#治疗中重度#特应性皮炎#的疗效和安全性，#spesolimab#

J Eur Acad Dermatol Venereol：司柏索利单抗治疗中重度特应性皮炎的疗效和安全性

2023-02-22发表于上海

循证小兵 (审核中...)

前往app查看评论内容

#勃林格殷格翰##IL-36R#单抗#佩索利单抗##spesolimab#治疗#泛发性脓疱型银屑病#

勃林格殷格翰IL-36R单抗spesolimab治疗银屑病在中国获批

2022-12-16发表于上海

lifestar (审核中...)

前往app查看评论内容

#FDA#批准的创新药物，如#呋替巴替尼#，#deucravacitinib#，#spesolimab#，#Selpercatinib#，#eflapegrastim#等，#肿瘤#，皮肤风湿免疫仍然是大头。下部分应是#罕见病#一类

FDA在2022年第三季度批准了哪些创新药（上）？

2022-10-10

科室
- - 订阅+
  - 更多科室
工具
服务